Article Per Year (5 Year)
p-Index From 2019 - 2024
0.562
P-Index
This Author published in this journals
All Journal Ophthalmologica Indonesiana Ophthalmologica Indonesiana
Umar Mardianto
Unknown Affiliation
Health Professions Medicine & Pharmacology Physics Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
EFFICACY OF ATROPINE SULPHATE EYE DROPS IN CONTROLLING MYOPIA PROGRESSION: A REVIEW Arcci Pradessatama; Umar Mardianto
Majalah Oftalmologi Indonesia Vol 49 No 1 (2023): Ophthalmologica Indonesiana
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/journal.v49i1.100681

Abstract

Introduction: Myopia is major public health concern that has become increasingly common. Severe myopia has become one of the main causes of untreatable vision loss throughout the world, often due to its irreversible complications. Studies shows atropine can reduce myopia progression in children. Currently, there are no guidelines for the use of atropine specifically to control myopia progression. This study was made to review the efficacy of various atropine doses in controlling myopia progression. Methods: Literature searching was conducted in four online databases (PubMed, EBSCOhost, ScienceDirect, and Scopus. Search terms included were “Atropine” and “Myopia”. Validity was assessed using assessment tool from Cochrane. Efficacy was evaluated using myopia progression in spherical equivalent per year and axial lengthening per year. Results: Sixteen randomized controlled trial studies fulfilled our inclusion criteria and eligibility screening. Overall, atropine shows favorable results in spherical equivalent progression (D/year) compared to control, with SMD = -1.13, 95% CI (-0.58, -1.68). Less axial elongation (mm/year) was observed in atropine group, with SMD = -1.28, 95% CI (-0.18, -2.37). Atropine 0.01% concentration shows overall significantly better myopia progression and axial lengthening compared to control, with SMD = -0.76, 95% CI (-0.08, -1.44) and SMD = -0.63, 95% CI (-0.14, -1.12), respectively. Higher atropine doses showed larger effect sizes with higher occurrence of adverse effects. Conclusion: Atropine eye drops in various doses shows overall effective myopia control in spherical equivalent and axial lengthening. Atropine 0.01% has significant myopia progression inhibition with less adverse effects than higher doses.
EFFICACY OF ATROPINE SULPHATE EYE DROPS IN CONTROLLING MYOPIA PROGRESSION: A REVIEW Arcci Pradessatama; Umar Mardianto
Majalah Oftalmologi Indonesia Vol 49 No 1 (2023): Ophthalmologica Indonesiana
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/journal.v49i1.100681

Abstract

Introduction: Myopia is major public health concern that has become increasingly common. Severe myopia has become one of the main causes of untreatable vision loss throughout the world, often due to its irreversible complications. Studies shows atropine can reduce myopia progression in children. Currently, there are no guidelines for the use of atropine specifically to control myopia progression. This study was made to review the efficacy of various atropine doses in controlling myopia progression. Methods: Literature searching was conducted in four online databases (PubMed, EBSCOhost, ScienceDirect, and Scopus. Search terms included were “Atropine” and “Myopia”. Validity was assessed using assessment tool from Cochrane. Efficacy was evaluated using myopia progression in spherical equivalent per year and axial lengthening per year. Results: Sixteen randomized controlled trial studies fulfilled our inclusion criteria and eligibility screening. Overall, atropine shows favorable results in spherical equivalent progression (D/year) compared to control, with SMD = -1.13, 95% CI (-0.58, -1.68). Less axial elongation (mm/year) was observed in atropine group, with SMD = -1.28, 95% CI (-0.18, -2.37). Atropine 0.01% concentration shows overall significantly better myopia progression and axial lengthening compared to control, with SMD = -0.76, 95% CI (-0.08, -1.44) and SMD = -0.63, 95% CI (-0.14, -1.12), respectively. Higher atropine doses showed larger effect sizes with higher occurrence of adverse effects. Conclusion: Atropine eye drops in various doses shows overall effective myopia control in spherical equivalent and axial lengthening. Atropine 0.01% has significant myopia progression inhibition with less adverse effects than higher doses.
Corneal Rigid Gas Permeable Contact Lens in Corneal Scarring: a Case Report: Poster Presentation - Case Report - Resident Regina Ivanovna; Umar Mardianto
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/15qnvb79

Abstract

Introduction : Corneal scarring is part of corneal wound healing response to injury, surgery, or infection to the cornea. Corneal scarring causes significant visual reduction. This case report highlights visual acuity (VA) improvement in patient with corneal scarring following rigid glass permeable contact lens (RGP-CL) Case Illustration : A 25 year-old male presented blurry vision in right eye (RE) due to trauma. His VA was 3/60 on RE and 6/6 on left eye (LE). The best corrected visual acuity (BCVA) of RE was 6/45 (S-1.25 C-5.00 X 180°). Slit lamp examination of RE showed corneal scarring in central area and deep neovascularization. Keratometry readings obtained 39.50D (8.48mm) at 170 degree and vertical curvature of 44.00D (7.68mm) at 80 degree, with markedly irregular mires of RE. A trial fitting was performed for RE by using tisilfocon A lens with base curve of 8.30 mm, power S-4.00D and diameter 9.20 mm. The over-refraction with trial lens obtained a total refractive error of S-6.00 with cylindrical correction neutralize with RGP. The achieved BCVA by over-refraction was 6/45 with comfortable fit. Discussion : Rigid permeable lens (RGP) is an option in dealing with irregular astigmatism due to corneal scarring. The RGP fitting works best especially when the corneal scarring is not in the center of visual pathway. Rigid lens works by providing tear-lens power and creating smooth surface to neutralize the irregular cornea. Good RGP-CL fitting could help patient with corneal carring gain better VA. Conclusion : Good rigid permeable contact lens fitting could help patients with corneal scarring gain better VA.
Co-Authors Arcci Pradessatama Regina Ivanovna